Thermo Fisher Q3 Revenue Rises 9% to $12.14 Billion, Net Income Up 6.2%; Adjusted EPS Grows 15%

Thermo Fisher Scientific Inc. (TMO) reported Wednesday that third-quarter revenue rose 9% to $12.14 billion from $11.12 billion a year earlier, while net income attributable to the company increased about 6.2% to $1.721 billion, or $4.64 per diluted share. For the quarter ended September 26, 2026, adjusted net income rose to $2.50 billion, or $6.68 per diluted share, from $2.19 billion, or $5.79 a year earlier, with adjusted diluted EPS up 15%. Operating income increased 17% to $2.263 billion. Laboratory Products and Biopharma Services revenue climbed to $6.863 billion from $5.970 billion, while Specialty Diagnostics declined to $1.098 billion from $1.174 billion. Cash, cash equivalents and short-term investments totaled $6.061 billion. Thermo Fisher said it will provide updated 2026 guidance on its earnings call at 7 a.m. ET Wednesday. TMO closed Tuesday at $687.37, up 1.18%, and fell 1.14% to $680 in premarket trading.